Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor

Journal of Medicinal Chemistry

Volumn 39, Issue 1, 1996, Pages 267-276

  Bridges, Alexander J ^a   Zhou, Hairong ^a   Cody, Donna R ^a   Rewcastle, Gordon W ^b   McMichael, Amy ^a   Showalter, H D Hollis ^a   Fry, David W ^a   Kraker, Alan J ^a   Denny, William A ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; DRUG ANALOG; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE;

ARTICLE; DRUG DEVELOPMENT; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

ANILINE COMPOUNDS; BINDING SITES; BLOTTING, WESTERN; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; HUMANS; KINETICS; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PHOSPHORYLATION; PROTEIN BINDING; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0030039555     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9503613     Document Type: Article

References (36)

1. Powis, G.; Workman, P. Signalling targets for the development of cancer drugs. Anti-Cancer Drug Des. 1994, 5, 263-277.
2. El-Zayat, A. A. E.; Pingree, T. F.; Mock, P. M.; Clark, G. M.; Otto, R. A.; Von Hoff, D. D. Epidermal growth factor receptor amplification in head and neck cancer. Cancer J. 1991, 4, 375-380.
3. Morishige, K.; Kurachi, H.; Amemiya, K.; Fujita, Y.; Yamamoto, T.; Miyake, A.; Tanizawa, O. Evidence for the involvement of transforming growth factor a and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro. Cancer Res. 1991, 51, 5322-5328.
4. Jardines, L.; Weiss, M.; Fowble, B.; Greene, M. Neu (c-erbB-2/ HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology 1993, 61, 268-282.
5. Hickey, K.; Grehan, D.; Reid, I. M.; O'Brian, S.; Walsh, T. N.; Hennessy, T. P. J. Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy. Cancer 1994, 74, 1693-1698.
6. Dobrusin, E. M.; Fry, D. W. Protein tyrosine kinases and cancer. Annu. Rep. Med. Chem. 1992, 27, 169-178.
7. Chang, C.-J.; Geahlen, R. L. Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J. Nat. Prod. 1992, 55, 1529-1560.
8. Levitski, A.; Gazit, A. Tyrosine kinase inhibition; An approach to drug development. Science 1995, 267, 1782-1788.
9. Palmer, B. D.; Rewcastle, G. W.; Thompson, A. M.; Boyd, M.; Showalter, H. D. H.; Sercel, A. D.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine kinase inhibitors. 4. Structure-activity relationships among N- and 3-substituted 2,2′-dithiobis(1H-indoles) for in vitro inhibition of receptor and nonreceptor protein tyrosine kinases. J. Med. Chem. 1995, 38, 58-67.
10. Barker, A. J.; Davies, D. H. Eur. Patent Appl. No. 0 520 722 A1, 1992.
11. Barker, A. J. Eur. Patent Appl. No. 0 566 226 A1, 1993.
12. Ward, W. H. J.; Cook, P. N.; Slater, A. M.; Davies, D. H.; Holdgate, G. A.; Green, L. R. Epidermal growth factor receptor. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 1994, 48, 659-666.
13. Fry, D. W.; Kraker, A. J.; McMichael, A.; Ambroso, L. A.; Nelson, J. M.; Leopold, W. R.; Connors, R. W.; Bridges, A. J. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994, 265, 1093-1095.
14. Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Zhou, H.; Cody, D. R.; McMichael, A.; Fry, D. W. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-(phenylmethyl)amino- and 4-phenylaminoquinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J. Med. Chem. 1995, 38, 3482-3487.
15. Hanks, S. K.; Quinn, A. M.; Hunter, T. The protein kinase family; conserved features and deduced phylogeny of the catalytic domains. Science 1988, 241, 42-52.
16. Leonard, N. J.; Morrice, A. G.; Sprecker, M. A. Linear benzoadenine. A stretched-out analog of adenine. J. Org. Chem. 1975, 40, 356-363.
17. Yoneda, T.; Lyall, R. M.; Alsina, M. M.; Persons, P. E.; Spada, A. P.; Levitski, A.; Zilberstein, A.; Mundy, G. R. The antiproliferative effects of tyrosine kinase inhibitors tyrphostins on a human squamous cell carcinoma in vitro and in nude mice. Cancer Res. 1991, 51, 4430-4435.
18. Traxler, P. M.; Wacker, O.; Bach, H. L.; Geissler, J. F.; Kump, W.; Meyer, T.; Regenass, U.; Roesel, J. L.; Lydon, N. Sulfonylbenzoyl-nitrostyrenes: potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase. J. Med. Chem. 1991, 34, 2328-2337.
19. Umezawa, H.; Imoto, M.; Sawa, T.; Isshiki, K.; Matsuda, N.; Uchida, T.; Iinuma, H.; Hamada, M.; Takeuchi, T. Studies on a new epidermal growth factor-receptor kinase inhibitor, erbstatin, produced by MH435-hF3. J. Antibiot. 1986, 39, 170-173.
20. Morley, J. S.; Simpson, J. C. E. The chemistry of simple heterocyclic systems. Part 1. Reactions of 6- and 7-nitro-4-hydroxyquinazoline and their derivatives. J. Chem. Soc. 1948, 360-366.
21. Cleland, W. W. Statistical analysis of enzyme kinetic data. Methods Emzymol. 1979, 103-138.
22. Denny, W. A.; Atwell, G. J.; Cain, B. F. Potential Antitumor Agents. 26. Anionic congeners of the 9-anilinoacridines. J. Med. Chem. 1978, 21, 5-10.
23. Hubbard, S. R.; Wei, L.; Ellis, L.; Hendrickson, W. A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 1994, 372, 746-754.
24. Rossmann, M. G.; Arnold, E.; Erickson, J. W.; Frankenberger, E. A.; Griffith, J. P.; Hecht, H.-J.; Johnson, J. E.; Kamer, G.; Luo, M.; Mosser, A. G.; Rueckert, R. R.; Sherry, B.; Vriend, G. Structure of a human common cold virus and functional relationship to other picornaviruses. Nature 1985, 317, 145-153.
25. Smith, T. J.; Kremer, M. J.; Luo, M.; Vriend, G.; Arnold, E.; Kamer, G.; Rossmann, M. G.; McKinlay, M. A.; Diana, G. D.; Otto, M. J. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science 1986, 233, 1286-1293.
26. Zhang, F.; Strand, A.; Robbins, D.; Cobb, M. H.; Goldsmith, E. J. Atomic structure of the MAP kinase ERK2 at 2.3 Å resolution. Nature 1994, 367, 704-711.
27. (a) Zheng, J.; Knighton, D. R.; Ten Eyck, L. F.; Karlsson, R.; Xuong, N.-H.; Taylor, S. S.; Sowadski, J. M. Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor. Biochemistry 1993, 32, 2154-2161.
28. 2+ adenylyl imidodiphosphate and inhibitor peptide PKI(5-24). EMBO J. 1993, 12, 849-859.
29. (a) Maillard, J.; Benard, M.; Vincent, M.; Vo-Van-Tri; Jolly, R.; Morin, R.; Benharkarte, Mrs.; Menillet, C. 3H-Quinazolin-4-one derivatives with antiinflammatory activity. II. Derivatives substituted in the aromatic nucleus, and related compounds. Chim. Ther. 1967, 2, 231-239.
30. (b) Chien, P.-L.; Cheng, C. C. Structural modification of febrifugine. Some methylenedioxy analogs. J. Med. Chem. 1970, 13, 867-870.
31. (c) Simpson, W. R. J. Bi-4-[l-(quinazolinyl-4)piperidyls] and bis4-[1-(quinazolinyl-4)piperidyl-] alkanes. U.S. Patent 4,011,323, 1977; Chem. Abstr. 1977, 87, 6013z.
32. (d) Takase, Y.; Saeki, T.; Watanabe, N.; Adachi, H.; Souda, S.; Saito, I. Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. J. Med. Chem. 1994, 37, 2106-2111.
33. Armarego, W. L. F.; Smith, J. I. C. Quinazolines. Part IX. Covalent hydration in the neutral species of substituted quinazolines. J. Chem. Soc. B 1967, 449-454.
34. Coppola, G. M.; Schuster, H. F. The chemistry of 2H-3,1-benzoxazine-2,4(1H)-dione (isatoic anhydride). 21. Amild process for the preparation of 10-alkyl-9-acridanones and it's application to the synthesis of acridone alkaloids. J. Heterocycl. Chem. 1989, 26, 957-964.
35. Kreutzberger, A.; Uzbek, M. U. Ringschluss zum chinazolon-(4)-system durch aminomethinylierung. (Synthesis of the 4(3H)-quinazolinone ring system through aminomethenylation.) Arch. Pharmacol. 1972, 305, 171-175.
36. Gill, G. N.; Weber, W. Purification of functionally active epidermal growth factor receptor protein using a competitive antagonist monoclonal antibody and competitive elution with epidermal growth factor. Methods Enzymol. 1987, 146, 82-88.